Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2, 2004. The report details specific corporate actions regarding directors' interests in company shares and a share repurchase transaction executed on August 31, 2004.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes and share ownership details.
- Share Repurchase Price: 1,135.50 pence per share.
- Shares Purchased: 750,000 Ordinary Shares.
- Total Treasury Shares Held: 40,068,000 shares (post-transaction).
- Shares in Issue: 5,894,208,451 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program authorized at the Annual General Meeting on May 17, 2004. Additionally, the GSK Trust transferred 4,382 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on August 31, 2004.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the share buyback and the administration of the employee trust. The filing explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction. No specific risks, contingencies, or forward-looking guidance regarding operations or financial performance are included in this document.
Key Facts for Investor Verification
- Verify the total cost of the 750,000 share repurchase (750,000 shares x 1,135.50 pence).
- Confirm the impact of the 40,068,000 treasury shares on earnings per share calculations in subsequent reports.
- Check the status of the remaining authority for share buybacks granted at the May 17, 2004 AGM.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding the 4,382 shares transferred.